MDMA Therapy 2026 Update: Where Things Stand After the FDA Rejection

What Happened With the FDA and Lykos

In August 2024, the FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics, the company that had filed a New Drug Application for MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder. The letter declined approval and asked Lykos to conduct a third Phase 3 clinical trial before resubmitting.

The FDA’s concerns centered on three areas: the durability of treatment effects over time, safety reporting reliability, and the near-impossibility of adequately blinding participants in MDMA trials (since the drug’s subjective effects make it obvious whether someone received the active dose or a placebo). There were also questions about how trial sites had been instructed to categorize certain euphoria-like effects, and whether prior MDMA use among some participants may have influenced results.

MAPS, the nonprofit that incubated Lykos, pushed back sharply. Their position is that the FDA agreed to the original Phase 3 study design in 2017 through a formal Special Protocol Assessment process, then shifted its standards after the trials were already complete. Whether that characterization is fully accurate remains disputed, but the underlying frustration is understandable: millions of people with PTSD have no new FDA-approved treatment options, and the Phase 3 data showed meaningful clinical results.

Since the rejection, Lykos cut roughly 75 percent of its staff and has since rebranded as Resilient Pharmaceuticals. The company has stated it is continuing negotiations with the FDA. A third Phase 3 trial is the likely path to resubmission, though no confirmed timeline exists for when that data would be available.

What the Clinical Evidence Actually Shows

Setting aside the regulatory dispute, the Phase 3 trial data itself is worth understanding clearly. The MAPP1 and MAPP2 studies found that approximately 67 percent of participants who received MDMA-assisted therapy no longer met criteria for PTSD after treatment, compared to around 32 percent in the placebo-plus-therapy group. Effect sizes were moderate to large. These are clinically meaningful numbers for a condition that has had no new approved pharmacological treatments in over two decades.

What the FDA wanted more clarity on is how long those effects last, and whether the benefit-risk calculation holds up across a more diverse patient population under more rigorous monitoring conditions. Those are legitimate scientific questions, even if the timing and framing of the request remains contested.

MDMA works through a distinct pharmacological mechanism compared to classic psychedelics like psilocybin. It primarily triggers the release of serotonin, dopamine, and norepinephrine, and also increases oxytocin levels. The result is a state of heightened emotional openness, reduced fear response, and increased sense of social connection, without the significant perceptual distortions or ego dissolution that characterize a psilocybin or LSD experience. This is why researchers have described it as particularly suited to trauma processing work: people can remain cognitively present while accessing painful material with reduced defensive reactivity.

MDMA PTSD Treatment FDA Status: Where Things Stand in 2026

The current MDMA PTSD treatment FDA status is straightforward: MDMA remains Schedule I, and there is no approved clinical use in the United States outside of research settings. The FDA’s Expanded Access (compassionate use) program that had allowed some open-label access between 2022 and the rejection is no longer active for MDMA, given that Schedule I status effectively excludes substances from most compassionate use pathways.

Clinical trials are the primary legal route. A search of ClinicalTrials.gov shows over 100 active and recruiting MDMA studies, including trials at VA medical centers examining MDMA-assisted therapy in veterans, and Phase 2 studies comparing MDMA-AT to alternative comparator conditions. The Department of Veterans Affairs has also signaled growing interest, with VA Secretary Doug Collins visiting an MDMA trial site and publicly referencing the VA’s approximately 12 active psychedelic clinical trials. Bipartisan legislation has been introduced in Congress to expand trial access and establish VA centers of excellence in psychedelic medicine.

Internationally, Australia remains the most accessible legal framework. As of 2023, Australian authorized prescribers can legally administer MDMA for PTSD under strict regulatory conditions. This is the only country where MDMA has been explicitly approved for clinical therapeutic use, and for some seekers with severe, treatment-resistant PTSD, it represents a real consideration if travel is feasible.

MAPS MDMA Therapy Access and What the Organization Is Doing Now

MAPS, which funded and designed the original Phase 3 research program, has stated clearly that it will continue pushing forward. MAPS MDMA therapy access efforts now include training therapists in MDMA-assisted protocols, continuing to incubate research, and running humanitarian projects in high-trauma, low-resource contexts globally. Their position is that the path to approval, while delayed, is not closed.

For seekers in the United States, the most direct legitimate route to MDMA-AT right now is enrollment in an active clinical trial. These trials do involve real screening, therapeutic support, and follow-up care, and participants are not charged for the investigational treatment itself. ClinicalTrials.gov is the place to search for currently enrolling studies.

The Real Risks of Underground Access

Given the delays in legal access, some people with PTSD are turning to underground MDMA therapy practitioners. This is worth addressing honestly rather than dismissively, because the people considering it are often in genuine distress after years of treatment failure.

The core problem with unregulated MDMA access is not primarily moral; it is structural. The clinical model for MDMA-AT depends on specific elements: thorough medical screening before the session, a trained therapeutic dyad (typically two co-therapists), carefully calibrated dosing in a controlled environment, and structured preparation and integration support before and after the experience. Remove any of those elements and you are not approximating the clinical model. You are doing something categorically different, and the safety profile changes accordingly.

The pharmacological risks that proper screening is designed to catch are real. MDMA produces significant increases in heart rate and blood pressure during active sessions. For people with pre-existing cardiac conditions or hypertension, this creates genuine risk of serious adverse events. MDMA also stimulates serotonin release through mechanisms that interact dangerously with serotonergic medications. Combining MDMA with MAO inhibitors carries life-threatening risk of serotonin syndrome. Combining it with SSRIs, SNRIs, or tramadol also carries risk, and this matters enormously for PTSD populations, where serotonin-modulating medications are among the most commonly prescribed treatments. Research from the FDA Adverse Event Reporting System found that all documented cases of serotonin syndrome associated with MDMA occurred in people who had also taken one or more additional serotonergic substances, which underscores the importance of medication review before any session.

People with a personal or family history of psychosis, schizophrenia, or bipolar disorder with manic episodes are generally considered contraindicated for MDMA-AT. The empathogenic and stimulant properties of MDMA can destabilize those conditions rather than help them.

Beyond the pharmacological risks, the therapeutic relationship in MDMA-AT carries its own vulnerability. MDMA increases trust and emotional openness in ways that make the client highly susceptible to suggestion and boundary violations. The FDA advisory committee flagged this as a concern in the trial data, and there have been documented cases of boundary violations in both underground and research contexts. Vetting practitioners in unregulated settings is significantly harder than in a clinical trial, and the consequences of encountering an unqualified or unethical guide can be severe.

There is also the legal dimension. MDMA possession and distribution remains a federal felony in the United States. This is not a minor administrative consideration. It carries real consequences for both the seeker and the practitioner.

For a broader overview of which conditions and medications make psychedelic therapy inadvisable, see our post on Contraindications for Psychedelic Therapy.

What Seekers Can Do Now

If you are living with treatment-resistant PTSD and following this situation, the honest answer is that your options in the United States are limited but not zero. Enrolling in a clinical trial is the only legal pathway to MDMA-AT domestically. For those with the means and severity of need, Australia represents a real legal option internationally. For people not suited to MDMA-AT due to medical history or medication profile, other psychedelic modalities, including psilocybin-assisted therapy in legal Oregon or Colorado frameworks, may be worth exploring with proper guidance and screening.

What is not a reasonable option is proceeding without thorough medical screening, disclosure of all current medications, and genuinely qualified support. The potential benefits of MDMA-assisted therapy that the research demonstrates are real. So are the risks when the therapeutic container that produced those results is removed.

If you are trying to understand whether you are a candidate for any form of psychedelic-assisted therapy, or trying to navigate what is actually accessible to you right now, that is exactly the kind of conversation we have at JourneyOM. We do not point people toward unregulated access. We do help people think through what is safe, legal, and appropriate for their situation.